Swedbank AB Grows Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Swedbank AB boosted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 10.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,164,170 shares of the biopharmaceutical company's stock after acquiring an additional 1,136,800 shares during the quarter. Swedbank AB owned about 2.06% of Royalty Pharma worth $310,308,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Forsta AP Fonden grew its holdings in shares of Royalty Pharma by 0.7% in the fourth quarter. Forsta AP Fonden now owns 244,200 shares of the biopharmaceutical company's stock valued at $6,230,000 after purchasing an additional 1,800 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its position in Royalty Pharma by 8.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 548,761 shares of the biopharmaceutical company's stock valued at $13,999,000 after buying an additional 43,926 shares during the period. Blue Trust Inc. boosted its position in Royalty Pharma by 31.3% in the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 376 shares during the period. 1834 Investment Advisors Co. acquired a new position in shares of Royalty Pharma in the fourth quarter worth $242,000. Finally, Fifth Third Bancorp raised its stake in shares of Royalty Pharma by 187.1% in the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 997 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on RPRX shares. StockNews.com upgraded Royalty Pharma from a "hold" rating to a "buy" rating in a report on Tuesday, November 5th. Citigroup reduced their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a "buy" rating on the stock in a report on Friday, October 25th. Finally, TD Cowen upgraded shares of Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Royalty Pharma has an average rating of "Buy" and an average target price of $41.67.

Royalty Pharma Stock Up 0.0 %

Shares of NASDAQ:RPRX traded up $0.01 during trading on Wednesday, hitting $31.95. 5,471,112 shares of the company were exchanged, compared to its average volume of 4,350,162. The firm's 50 day moving average price is $27.01 and its 200-day moving average price is $27.44. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $32.21. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. The stock has a market capitalization of $18.82 billion, a P/E ratio of 16.55 and a beta of 0.47.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.22 per share. The ex-dividend date is Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.75%. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. Royalty Pharma's payout ratio is 43.52%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.